Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 8/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100929 | 0.88 | PIM1 (0.52) | PIM1PIM3PIM2CTSKMAP4K4 | |
| SCHEMBL2422225 | 0.88 | PIM1 (0.52) | PIM1PIM3PIM2CTSKMAP4K4 | |
| SCHEMBL2422222 | 0.88 | PIM1 (0.52) | PIM1PIM3PIM2CTSKMAP4K4 | |
| SCHEMBL15101022 | 0.88 | PIM1 (0.52) | PIM1PIM3PIM2CTSKMAP4K4 | |
| SCHEMBL12283936 | 0.87 | PIM1 (0.67) | PIM1PIM3PIM2CTSKMAP4K4 | |
| SCHEMBL18064896 | 0.87 | PIM1 (0.51) | PIM1PIM3PIM2CTSKMAP4K4 | |
| SCHEMBL12283371 | 0.83 | PIM1 (0.51) | PIM1PIM3PIM2CTSKSUV39H2 | |
| SCHEMBL12284239 | 0.83 | PIM1 (0.51) | PIM1PIM3PIM2CTSKSUV39H2 | |
| SCHEMBL18064902 | 0.83 | PIM1 (0.53) | PIM1PIM3PIM2CTSKMAP4K4 | |
| SCHEMBL12284284 | 0.83 | PIM1 (0.51) | PIM1PIM3PIM2CTSKSUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | PIM1 4678/4885PIM3 4115/4885PIM2 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.